Cargando…
Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
BACKGROUND: Extended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net cli...
Autores principales: | Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Lopes, Renato D., Gold, Alex, Cohen, Alexander T., Harrington, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586307/ https://www.ncbi.nlm.nih.gov/pubmed/28698258 http://dx.doi.org/10.1161/JAHA.117.006015 |
Ejemplares similares
-
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial
por: Gibson, C. Michael, et al.
Publicado: (2018) -
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
por: Yee, Megan K., et al.
Publicado: (2019) -
Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018) -
The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification
por: Gibson, C. Michael, et al.
Publicado: (2017) -
Pheochromocytoma Presenting as Partial HELLP Syndrome
por: Daaboul, Yazan, et al.
Publicado: (2015)